September 17th 2025
Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.
September 15th 2025
EyePoint Pharmaceutical's Phase 2 PAVIA falls short of primary endpoint
May 11th 2024While it fell short of the primary endpoint of improvement of non-proliferative diabetic retinopathy (NPDR) of at least 2 Diabetic Retinopathy Severity Scale (DRSS) levels as of week 36, DURAVYU did demonstrate stable or improved disease severity with reduced rates of NPDR in 9 months.
Read More
According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.
Read More
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
April 19th 2024According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.
Read More
Beyond the eclipse: The long-term effects of solar retinopathy
April 1st 2024Patients can experience solar retinopathy after viewing the eclipse without protection, but it also can occur from outdoor activities, including those mentioned. It can lead to symptoms that include blurry vision, vision loss at the center of a patient’s sight and eye pain.
Read More
Diagnosis and management of solar retinopathy
March 21st 2024Solar retinopathy is caused by prolonged or high intensity exposure of the fovea centralis to light energy. Suspected cases of solar retinopathy may require urgent referral to an ophthalmologist for diagnosis, and to eliminate treatable causes for central visual disturbance.
Read More